Neos Therapeutics Inc. (NASDAQ: NEOS)Penny Stocks To Watch #1: PharmaDrug Inc.
When you think about biotech, the first thing that might come to mind are labs designed for developing cancer treatments or vaccines. But have you thought about how this market niche has evolved over the last few years? With the inclusion of things like ânatural medicines,â weâve seen everything from cannabis to psychedelics being explored by companies. In this case, PharmaDrug is concentrating on both.
Specific to the pharmaceutical market potential of alternative medicines, the studies focusing on psychedelics primarily target mental health concerns. Weâre talking about a market (central nervous system therapeutics) worth nearly $205 billion by 2028. While the âcannabis playâ for PharmaDrug focuses on the German market, its advancement in R&D for psychedelics is getting much more attention. Furthermore, the company isnât âjust another mushroom stock.â Itâ�
Worldwide Industry for Pharmaceutical Treatments for Mental Health Disorders to 2025 - Snapshot of Products in Phase III Development for Selected Psychiatric Disorders
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
NEW YORK, Jan. 28, 2021 /PRNewswire/ Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated
Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating
Neos Therapeutics, Inc. ( NEOS or the Company ) (
) relating to its proposed merger with Aytu BioScience, Inc. Under the terms of the agreement, NEOS shareholders will receive 0.1088 shares of Aytu per share they own.
The investigation focuses on whether Neos Therapeutics, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, 2) whether the transaction is properly valued and 3) whether all material information has been disclosed.
Attention Deficit Hyperactivity Treatment Disorder (ADHD) 2021 Market Estimation, Dynamics, Outlook, Research, Trends and Forecasts To 2023
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.